BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

AstraZeneca India inks LoI with Strand Life Sciences

18 November 2026 | News

For exploring opportunities to collaborate in healthcare in India



AstraZeneca India has signed a Letter of Intent (LOI) with Strand Life Sciences, a genomics research and diagnostics company and a subsidiary of Reliance Industries Limited, to explore opportunities to collaborate in healthcare in India.

The collaboration brings together AstraZeneca Pharma India and Strand Life Sciences in a healthcare-focused partnership.

The disclosure, dated November 17, 2026, clarifies that the execution of the LOI does not constitute a related party transaction. AstraZeneca Pharma India and Strand Life Sciences are not related parties under applicable corporate governance norms.

Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India, said “The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease.”